Aberdeen Group
AMED

Aberdeen Group’s Amedisys AMED Stock Holding History

Aberdeen Group’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-169,023
Closed -$25.2M – 1046
2021
Q3 		$25.2M Sell
169,023
-41,794
-20% -$8.69M 0.06% 304
2021
Q2 		$51.6M Sell
210,817
-35,824
-15% -$9.4M 0.11% 177
2021
Q1 		$65.3M Buy
246,641
+1,733
+0.7% +$489K 0.15% 145
2020
Q4 		$71.9M Buy
244,908
+59,699
+32% +$15.3M 0.18% 122
2020
Q3 		$43.8M Buy
185,209
+70,305
+61% +$16M 0.12% 155
2020
Q2 		$22.8M Buy
114,904
+347
+0.3% +$64.7K 0.06% 275
2020
Q1 		$21M Buy
+114,557
New +$20.4M 0.07% 247

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Aberdeen Group's AMED Position: Q4 2021 in Review

Aberdeen Group sold out of Amedisys (AMED) in Q4 2021, closing a stake of 169,023 shares — an estimated $25.2M sold.

Aberdeen Group first reported a position in AMED in Q1 2020 and held it in 7 quarters. The position peaked at $71.9M in Q4 2020. 324 funds tracked by Wall St. Rank hold AMED as of Q4 2021.

  • Aberdeen Group reported no remaining Amedisys position as of Q4 2021 after selling out during the quarter.
  • Aberdeen Group sold 169,023 Amedisys shares in Q4 2021, an estimated $25.2M.
  • Aberdeen Group first reported a position in Amedisys in Q1 2020 and held it in 7 quarters.
  • Aberdeen Group's Amedisys position peaked at $71.9M in Q4 2020.
  • 324 funds tracked by Wall St. Rank held Amedisys as of Q4 2021.

Based on Aberdeen Group's 13F filing for Q4 2021, filed 8 Feb 2022.